Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 5/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.60 |
| ▸ | RXRA | P19793 | 4/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | RARB | P10826 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806543 | 0.88 | RXRB (0.59) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL30295343 | 0.88 | RXRB (0.59) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL20556574 | 0.87 | RXRB (0.79) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL10419228 | 0.86 | TDP1 (0.57) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL17908058 | 0.86 | RXRB (0.57) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL1356449 | 0.85 | TDP1 (0.71) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL31528338 | 0.85 | TDP1 (0.71) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL17998017 | 0.85 | TDP1 (0.56) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL28191970 | 0.84 | RXRB (0.58) | RXRBTDP1NR1H4RXRASRD5A2 | |
| SCHEMBL1070700 | 0.83 | TDP1 (0.79) | RXRBTDP1NR1H4RXRASRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109553704-B | Catalyst component for olefin polymerization, catalyst and application | 中国石油化工股份有限公司 | 2021-04-13 | — | — | CN | claimed |
| EP-2516479-B1 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF CORP (US) | 2016-04-20 | — | — | EP | claimed |
| EP-2516479-A2 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF Corporation (US) | 2012-10-31 | — | — | EP | claimed |
| US-8211819-B2 | Internal and external donor compounds for olefin polymerization catalysts | BASF CORPORATION (US) | 2012-07-03 | — | — | US | claimed |
| WO-2011084691-A2 | NEW INTERNAL AND EXTERNAL DONOR COMPOUNDS FOR OLEFIN POLYMERIZATION CATALYSTS | BASF CORPORATION (US) | 2011-07-14 | — | — | WO | claimed |
| US-20110152481-A1 | Internal and external donor compounds for olefin polymerization catalysts | BASF CATALYSTS LLC (US) | 2011-06-23 | — | — | US | claimed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119242013-A | Flame retardant material, preparation method thereof and product | 江苏博云塑业股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-119081387-A | Flame retardant material, preparation method and product thereof | 江苏博云塑业股份有限公司 | 2024-12-06 | — | — | CN | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| WO-2003084968-A1 | POLYDIOXABORINES, THEIR MONOMERS AND THEIR PREPARATION | NITTO DENKO CORPORATION (JP) | 2003-10-16 | — | — | WO | disclosed |
| EP-0498603-B1 | Olefin polymerization and copolymerization process | AMOCO CORP (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0736552-A2 | Propylene homopolymer | AMOCO CORPORATION (US) | 1996-10-09 | — | — | EP | disclosed |
| US-5218052-A | Increased stiffness and broadend molecular weight distribution | AMOCO CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| EP-0498603-A2 | Olefin polymerization and copolymerization process | AMOCO CORPORATION (US) | 1992-08-12 | — | — | EP | disclosed |
| US-4916470-A | Image bar with electrochromic switching system | XEROX CORPORATION (US) | 1990-04-10 | — | — | US | disclosed |
| US-4910206-A | Endotoxin induced lung injury | SANDOZ PHARMACEUTICALS CORP. (US) | 1990-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | RXRB 2417/4885TDP1 3607/4885NR1H4 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.